Abstract
Background: Although gastroesophageal reflux disease (GERD) causes noncardiac chest pain mimicking angina peetons, systemic studies surveying the effects of common cardiac drugs on symptomatic GERD are rare. Methods: To investigate the drug- related GER.1), this multicenter trial enrolled 201 consecutive cardiac outpatients (69.7 ±10.5 y) after obtaining written infomied consent. They were assessed using the Frequency Scale for Symptoms of GERD (F-scale) to screen for GERD with a cut-off value of 8.0. Clinical background was obtained from medical records. Gastric medicine was empirically administered at the discretion of the attending physician. F-scale score and incidence of GERI) were analyzed individually in relation to background and prescription. Results: The avenge F-scale score did not correlate with gender, age or underlying diseases. F-scale score was elevated significantly (p - 0.006) by administration of calcium channel blockers to the patients treated with gastric medicine, suggesting that calcium channel blockers exacerbate the possibly preexisting GERD. Incidence of GERD within 2 months after starting warfarin tended to be greater than that at other durations (p = 0.087). Patients showing a high score (≥ 8.0) suggestive of GERD showed a correlation with the combined administration of calcium channel blockers (OR 3.19; 95% CI of 1.01 - 10.11; p = 0.049) and warfarin (OR = 3.05; 95% CI of 1.00- 9.27; p = 0.049) in the best logistic model. Conclusion: Although larger cohort is required, this survey demonstrates that the combination of calcium channel blockers and warfarin is an independent risk factor for GERD.
| Original language | English |
|---|---|
| Pages (from-to) | 555-563 |
| Number of pages | 9 |
| Journal | International Journal of Clinical Pharmacology and Therapeutics |
| Volume | 49 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - Sep 2011 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology
- Pharmacology (medical)
Cite this
Influence of common cardiac drugs on gastroesophageal reflux disease : Multicenter questionnaire survey. / Nakaji, G.; Fujihara, M.; Fukata, Mitsuhiro; Yasuda, S.; Odashiro, Keita; Maruyama, Toru; Akashi, Koichi.
In: International Journal of Clinical Pharmacology and Therapeutics, Vol. 49, No. 9, 09.2011, p. 555-563.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Influence of common cardiac drugs on gastroesophageal reflux disease
T2 - Multicenter questionnaire survey
AU - Nakaji, G.
AU - Fujihara, M.
AU - Fukata, Mitsuhiro
AU - Yasuda, S.
AU - Odashiro, Keita
AU - Maruyama, Toru
AU - Akashi, Koichi
PY - 2011/9
Y1 - 2011/9
N2 - Background: Although gastroesophageal reflux disease (GERD) causes noncardiac chest pain mimicking angina peetons, systemic studies surveying the effects of common cardiac drugs on symptomatic GERD are rare. Methods: To investigate the drug- related GER.1), this multicenter trial enrolled 201 consecutive cardiac outpatients (69.7 ±10.5 y) after obtaining written infomied consent. They were assessed using the Frequency Scale for Symptoms of GERD (F-scale) to screen for GERD with a cut-off value of 8.0. Clinical background was obtained from medical records. Gastric medicine was empirically administered at the discretion of the attending physician. F-scale score and incidence of GERI) were analyzed individually in relation to background and prescription. Results: The avenge F-scale score did not correlate with gender, age or underlying diseases. F-scale score was elevated significantly (p - 0.006) by administration of calcium channel blockers to the patients treated with gastric medicine, suggesting that calcium channel blockers exacerbate the possibly preexisting GERD. Incidence of GERD within 2 months after starting warfarin tended to be greater than that at other durations (p = 0.087). Patients showing a high score (≥ 8.0) suggestive of GERD showed a correlation with the combined administration of calcium channel blockers (OR 3.19; 95% CI of 1.01 - 10.11; p = 0.049) and warfarin (OR = 3.05; 95% CI of 1.00- 9.27; p = 0.049) in the best logistic model. Conclusion: Although larger cohort is required, this survey demonstrates that the combination of calcium channel blockers and warfarin is an independent risk factor for GERD.
AB - Background: Although gastroesophageal reflux disease (GERD) causes noncardiac chest pain mimicking angina peetons, systemic studies surveying the effects of common cardiac drugs on symptomatic GERD are rare. Methods: To investigate the drug- related GER.1), this multicenter trial enrolled 201 consecutive cardiac outpatients (69.7 ±10.5 y) after obtaining written infomied consent. They were assessed using the Frequency Scale for Symptoms of GERD (F-scale) to screen for GERD with a cut-off value of 8.0. Clinical background was obtained from medical records. Gastric medicine was empirically administered at the discretion of the attending physician. F-scale score and incidence of GERI) were analyzed individually in relation to background and prescription. Results: The avenge F-scale score did not correlate with gender, age or underlying diseases. F-scale score was elevated significantly (p - 0.006) by administration of calcium channel blockers to the patients treated with gastric medicine, suggesting that calcium channel blockers exacerbate the possibly preexisting GERD. Incidence of GERD within 2 months after starting warfarin tended to be greater than that at other durations (p = 0.087). Patients showing a high score (≥ 8.0) suggestive of GERD showed a correlation with the combined administration of calcium channel blockers (OR 3.19; 95% CI of 1.01 - 10.11; p = 0.049) and warfarin (OR = 3.05; 95% CI of 1.00- 9.27; p = 0.049) in the best logistic model. Conclusion: Although larger cohort is required, this survey demonstrates that the combination of calcium channel blockers and warfarin is an independent risk factor for GERD.
UR - http://www.scopus.com/inward/record.url?scp=80052987385&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052987385&partnerID=8YFLogxK
U2 - 10.5414/CP201558
DO - 10.5414/CP201558
M3 - Article
VL - 49
SP - 555
EP - 563
JO - International Journal of Clinical Pharmacology and Therapeutics
JF - International Journal of Clinical Pharmacology and Therapeutics
SN - 0946-1965
IS - 9
ER -